National Biotech Calls Its Second Annual General Meeting

12th October 2025, Kathmandu

In a move that signals a major transformation for Nepal’s agricultural technology landscape, National Biotech Private Limited has officially announced the convening of its second Annual General Meeting (AGM). This upcoming assembly is not just a routine corporate event; it is a critical step on the company’s “Roadmap for an IPO” that will soon transition Nepal’s first internationally certified organic company from private ownership to a publicly listed entity on the capital market

National Biotech Calls AGM

The decision to hold this pivotal AGM was formalized during the company’s recent board meeting on Tuesday. The assembly is scheduled for November 21 (Mangsir 5), and all shareholders are urged to attend this significant gathering, set to take place at the A-One Café and Party Palace in Naya Bazaar, Kathmandu.

The Core Agenda: Unleashing the Power of Public Investment

The central and most impactful item on the agenda for the Second Annual General Meeting is the proposal to issue ordinary shares to the general public, the final step before a full Initial Public Offering (IPO). This strategic financial maneuver is designed to raise substantial capital, which National Biotech plans to inject directly into scaling up its operations and expanding its market reach both domestically and potentially internationally.

As the market leader in high-quality organic fertilizer in a granular form, National Biotech is well-positioned to capitalize on the growing global demand for sustainable and organic agricultural inputs. The IPO funds are crucial for reinforcing the company’s status as a leader in Nepal’s green economy.

A Special Offer to the General Public: The AGM will table a proposal specifically for a “special offer” of ordinary shares. This is the mechanism by which the company will transition to public status, inviting thousands of new retail and institutional investors to own a piece of Nepal’s leading organic agri-tech firm.

Capital Utilization and Transparency: A key point of discussion will be the detailed plan for utilizing the capital generated from this public share issuance. The company is committed to transparently outlining how the funds will be deployed to maximize shareholder value, which is vital for building investor confidence during an IPO process.

Corporate Governance and Legal Amendments: To facilitate this move to public ownership, the AGM will seek shareholder approval for necessary amendments to the company’s Memorandum of Association and Articles of Association. These changes are mandatory to align the company’s internal regulations with the stringent compliance requirements for publicly traded companies under the Companies Act, 2063.

Board Authorization: The meeting will also grant the necessary authority to the Board of Directors to execute the entire share issuance process, including managing all related banking transactions and regulatory submissions, ensuring a smooth and efficient public offering.

Reviewing the Foundations: Financial Health and Compliance

Beyond the forward-looking IPO proposal, the AGM will fulfill its fundamental obligation to review the company’s performance and ensure compliance with regulatory standards. This demonstrates National Biotech’s commitment to solid governance as it prepares for public scrutiny.

Endorsement of Fiscal Year 2081/82 Reports: Shareholders will review and endorse the company’s annual report for the fiscal year 2081/82 B.S. The document will provide a comprehensive overview of the company’s operational performance, market achievements, and strategic direction over the last twelve months.

Approval of Audited Financial Statements: Crucially, the meeting will approve the audited financial statements up to the end of Ashadh 2082. The audit report, prepared in compliance with local financial regulations, is essential to confirm the company’s financial health and stability, a prerequisite for any public offering.

Auditor Appointment for 2082/83: In line with Section 111 of the Companies Act, 2063, the AGM will appoint the auditor for the upcoming fiscal year, 2082/83 B.S., and finalize their remuneration. This routine yet important task ensures continuity in financial oversight.

The Bigger Picture: National Biotech’s Journey to Public Ownership
National Biotech’s decision to pursue an IPO is not sudden. As far back as March 2023, the company had already signed a “Roadmap for an IPO” agreement with NIBL Ace Capital Limited, demonstrating a long-term, calculated strategy for public listing. NIBL Ace Capital, known for its corporate advisory services, will be instrumental in guiding the company through the complex pre-IPO and IPO phases.

National Biotech has already established itself as a pioneer in the market. It is Nepal’s first internationally certified organic company and is a significant provider of organic products, including animal-based and plant-based organic fertilizers and various agriculture supplies. With a network of over 100 dealers and retailers across the country, the company’s infrastructure is ready to support a massive expansion fueled by public investment.

The IPO process itself is structured in two distinct phases:

Phase One (Pre-IPO): NIBL Ace Capital provided initial consulting on the preparatory work, focusing on capital structure, issue process, size, pricing, and assisting with the required documentation for converting the private limited company to a public limited company.

Phase Two (IPO): Following the successful conversion and approval at the AGM, NIBL Ace Capital will act as the official issue manager for the shares offered to the general public.

This Second AGM is the necessary legislative hurdle that confirms shareholder consent for the public issue, thereby enabling the transition and kickstarting the capital-raising phase. The successful completion of this assembly on November 20, 2025, will officially mark National Biotech’s commitment to becoming a publicly traded leader in sustainable agriculture, offering investors a unique opportunity to participate in the growth of Nepal’s burgeoning green economy.

Market Impact and Future Outlook

The entry of a specialized company like National Biotech into the capital market is expected to generate significant interest, especially among investors keen on the long-term potential of the agri-tech and biotechnology sectors. As global trends emphasize sustainability, organic farming, and food security, companies like National Biotech are positioned for strong, sustained growth. The capital raised will be used not only to boost production capacity but also potentially for research and development into new organic products, solidifying their competitive advantage.

This impending public issue reinforces the positive sentiment in the biotech sector, showcasing the ability of innovative, local companies to harness the public capital market for ambitious expansion plans. Shareholders and prospective investors should closely monitor the outcome of the November 20th AGM, as it is poised to be a landmark event for National Biotech and for the future of organic investment in the region.

For More: National Biotech Calls AGM